Abstract
Several nutritional assessment tools have been used in oncology settings to monitor nutritional status and its associated prognostic significance. Body composition is fundamental for the assessment of nutritional status. Recently, the use of accurate and precise body composition tools has significantly added to the value of nutritional assessment in this clinical setting. Computerized tomography (CT) is an example of a technique which provides state-of-the-art assessment of body composition. With use of CT images, a great variability in body composition of cancer patients has been identified even in people with identical body weight or body mass index. Severe muscle depletion (sarcopenia) has emerged as a prevalent body composition phenotype which is predictive of poor functional status, shorter time to tumor progression, shorter survival, and higher incidence of dose-limiting toxicity. Variability in body composition of cancer patients may be a source of disparities in the metabolism of cytotoxic agents. Future clinical trials investigating dose reductions in patients with sarcopenia and dose-escalating studies based on pre-treatment body composition assessment have the potential to alter cancer treatment paradigms.
Keywords: Body composition, cancer, cancer prognosis, chemotherapy treatment, nutritional assessment, nutritional status, pharmacokinetics.
Anti-Cancer Agents in Medicinal Chemistry
Title:Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics
Volume: 13 Issue: 8
Author(s): Carla M. M. Prado, Yara L. M. Maia, Michael Ormsbee, Michael B. Sawyer and Vickie E. Baracos
Affiliation:
Keywords: Body composition, cancer, cancer prognosis, chemotherapy treatment, nutritional assessment, nutritional status, pharmacokinetics.
Abstract: Several nutritional assessment tools have been used in oncology settings to monitor nutritional status and its associated prognostic significance. Body composition is fundamental for the assessment of nutritional status. Recently, the use of accurate and precise body composition tools has significantly added to the value of nutritional assessment in this clinical setting. Computerized tomography (CT) is an example of a technique which provides state-of-the-art assessment of body composition. With use of CT images, a great variability in body composition of cancer patients has been identified even in people with identical body weight or body mass index. Severe muscle depletion (sarcopenia) has emerged as a prevalent body composition phenotype which is predictive of poor functional status, shorter time to tumor progression, shorter survival, and higher incidence of dose-limiting toxicity. Variability in body composition of cancer patients may be a source of disparities in the metabolism of cytotoxic agents. Future clinical trials investigating dose reductions in patients with sarcopenia and dose-escalating studies based on pre-treatment body composition assessment have the potential to alter cancer treatment paradigms.
Export Options
About this article
Cite this article as:
Prado M. M. Carla, Maia L. M. Yara, Ormsbee Michael, Sawyer B. Michael and Baracos E. Vickie, Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (8) . https://dx.doi.org/10.2174/18715206113139990322
DOI https://dx.doi.org/10.2174/18715206113139990322 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells
Current Cancer Drug Targets Therapeutic Value of an Integrin Antagonist in Prostate Cancer
Current Drug Targets Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Does the Oxazolidinone Derivatives Constitute a Functional Approach for Cancer Therapy?
Clinical Cancer Drugs Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
Current Medicinal Chemistry Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer
Current Medicinal Chemistry Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Steroidal Cardiac Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors Exhibit Strong Anti-Cancer Potential <i>in vitro</i> and in Prostate and Lung Cancer Xenografts <i>in vivo</i>
Anti-Cancer Agents in Medicinal Chemistry Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Role of Infection Control in Prevention of Hepatitis B virus (HBV) in Hemodialysis (HD) Patients.
Infectious Disorders - Drug Targets